FDA, Labs, Vendors Take Steps Toward Regulatory Ground Rules for Array-Based Cytogenetic Testing

At a meeting hosted by the US Food and Drug Administration last week, FDA representatives made it clear that the agency will in the future require array manufacturers to seek clearance in order to sell their chips for use in clinical cytogenetics, though it has not yet reached a decision on what criteria it expects vendors to fulfill in order to achieve such clearance.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.